Abstract:Abstract Triple-negative breast cancer (TNBC) is an aggressive and recurrent type of breast cancer that accounts for over 15% of new diagnoses yearly. Patients with TNBC have limited response to hormonal or targeted therapies due to the lack of ER, PR, and HER2. Therefore, the standard treatment for TNBC is anthracycline/taxane-based chemotherapies, paclitaxel (PXL), and doxorubicin (DOX), for which patients often develop chemoresistance. PXL, particularly, induces metastasis in TNBC patients by activating the Toll-Like Receptor 4 (TLR4)/NFkB signaling pathway. Since there are few targeted therapies for TNBC, there is an urgent need to identify new “druggable” molecular targets. The oncogenic GTPases Rac and Cdc42, and their downstream effector, p-21 Activated Kinase (PAK), play critical roles in TNBC development and metastatic cancer progression. Therefore, we developed MBQ-167 as a potent Rac/Cdc42 inhibitor that decreases tumor cell growth and metastasis in TNBC mouse models with no apparent toxicity. To test the hypothesis that inhibiting Rac/Cdc42 with MBQ-167 will chemosensitize TNBC cells to PXL and DOX, we treated TNBC human cell lines MDA-MB-231 and MDA-MB-468 with different concentrations of MBQ-167 (250 nM-500 nM), PXL (5 nM-10 nM), DOX (250 nM-500 nM), and their combinations. The efficacy of single and combined treatments was determined on cell proliferation with the MTT assay, apoptosis with the Caspase-Glo 3/7 assay, and cell migration with the wound healing assay. In addition, we evaluated the effect of single or combined MBQ-167 (per oral 50 mg/kg, 5X a week) and PXL (IP 10mg/kg, 1X a week) on tumor growth and metastasis in an orthotopic Luciferase tagged-MDA-MB-468 TNBC mouse model. Our in vitro results demonstrate that treatments with MBQ-167, PXL, DOX, and their respective combinations, decreased TNBC cell viability and increased apoptosis compared to vehicle controls. Both combination treatments reduced cell viability and increased apoptosis compared to PXL or DOX alone. Moreover, MBQ-167 was more effective than PXL at reducing MDA-MB-231 cell migration. DOX treatment did not affect cell migration, while combination treatment of DOX with MBQ-167 decreased migration. Moreover, in the mouse model, MBQ-167 significantly reduced MDA-MB-468 mammary tumor growth by 85% compared to vehicle treatments. This decrease in tumor growth was comparable to PXL treatment alone and in combination with MBQ-167. As expected, PXL treatment increased metastasis to the lungs and liver, while MBQ-167 prevented lung and liver metastases and reduced PXL-induced metastasis. Therefore, inhibiting Rac/Cdc42 with MBQ-167 improves the responses to current TNBC chemotherapies, PXL and Dox, and reduces PXL-induced metastasis, making MBQ-167 a potential adjuvant treatment against TNBC. This conclusion will be tested since we recently obtained IND approval from the US FDA for MBQ-167 and plan to conduct clinical trials in TNBC patients. Citation Format: Nilmary Grafals-Ruiz, Ailed M. Cruz-Collazo, Anamaris Torres-Sánchez, Surangani Dharmawardhane. MBQ-167 chemosensitizes triple-negative breast cancer cells to current chemotherapies and reduces paclitaxel-induced metastasis [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P2-01-05.

11A-N-tosyl-5-deoxi-pterocarpan, LQB-223, a Novel Compound with Potent Antineoplastic Activity Toward Breast Cancer Cells with Different Phenotypes

Naphthoquinone-Quinolone Hybrids with Antitumor Effects on Breast Cancer Cell Lines—From the Synthesis to 3D-Cell Culture Effects

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

A Novel Compound from the Phenylsulfonylpiperazine Class: Evaluation of In Vitro Activity on Luminal Breast Cancer Cells

Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer

A Novel Pyrazole Exhibits Potent Anticancer Cytotoxicity via Apoptosis, Cell Cycle Arrest, and the Inhibition of Tubulin Polymerization in Triple-Negative Breast Cancer Cells

The More the Better-Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors

Anticancer Activity of Benzo[a]phenoxazine Compounds Promoting Lysosomal Dysfunction

The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress

In Vitro and In Vivo Relevant Antineoplastic Activity of Platinum(II) Complexes toward Triple-Negative MDA-MB-231 Breast Cancer Cell Line

Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo

Delanzomib, A Novel Proteasome Inhibitor, Sensitizes Breast Cancer Cells To Doxorubicin-Induced Apoptosis

Evaluation of the in vivo acute toxicity and in vitro genotoxicity and mutagenicity of synthetic β-carboline alkaloids with selective cytotoxic activity against ovarian and breast cancer cell lines

Benzoxazole derivatives as new generation of anti-breast cancer agents

Design and discovery of carboxamide-based pyrazole conjugates with multifaceted potential against Triple-Negative Breast cancer MDA-MB-231 cells

Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its Drug Metabolism and Pharmacokinetics In Vitro Profile

Synthesis, In Vitro, and In Vivo Investigations of Pterostilbene-Tethered Analogues as Anti-Breast Cancer Candidates

Hematopoietic Differentiation of Embryonic Stem Cells: An In Vitro Model to Study Gene Regulation during Megakaryocytopoiesis

Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4

Abstract P2-01-05: MBQ-167 chemosensitizes triple-negative breast cancer cells to current chemotherapies and reduces paclitaxel-induced metastasis

Burhenne technique for extraction of retained biliary calculi.